Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597377 | 0.93 | CDK1 (0.86) | CDK1CDK2CDK4 | |
| SCHEMBL21067956 | 0.92 | CDK2 (0.85) | CDK1CDK2CDK4 | |
| SCHEMBL6598229 | 0.91 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6596290 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6597223 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6595336 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6596436 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6597534 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6595545 | 0.90 | CDK1 (1.00) | CDK1CDK2CDK4 | |
| SCHEMBL6594007 | 0.88 | CDK1 (1.00) | CDK1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | claimed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | claimed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | claimed |
| US-20240034799-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS SINAI MEDICAL CENTER (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230406853-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | Umbra Therapeutics, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4256086-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Cedars-Sinai Medical Center (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022119842-A1 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-1280802-B1 | INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD (KR) | 2004-05-06 | — | — | EP | disclosed |
| US-6620831-B2 | Cyclin dependent kinase inhibitors; anticarcinogenic and antiinflammatory agents; restenosis, angiogenesis | LG LIFE SCIENCES LTD. (KR) | 2003-09-16 | — | — | US | disclosed |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | LG LIFE SCIENCES LTD. (KR) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDK1 2489/4885CDK2 2103/4885CDK4 2786/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK1 1952/4885CDK2 1489/4885CDK4 2893/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK1 1952/4885CDK2 1489/4885CDK4 2893/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDK1 2448/4885CDK2 1540/4885CDK4 4310/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK1 2325/4885CDK2 1981/4885CDK4 3472/4885 |
| US-20230406853-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | CDK2, CDK20, CDK2AP1 | CDK1 6/4885CDK2 1/4885CDK4 12/4885 |
| US-20030149034-A1 | INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION | CCNA1, CCNI, CCNT1 | CDK1 4/4885CDK2 13/4885CDK4 5/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDK1 3347/4885CDK2 2992/4885CDK4 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.